Retrograde Cricopharyngeal Dysfunction
Conditions
Interventions
Group 1: Retrospective observational cohort of patients diagnosed with retrograde cricopharyngeal dysfunction (RCPD) who underwent transoral endoscopic injection of 50 units of botulinum toxin A into
no comparator group was included.
Sponsors
Uniklinikum Düsseldorf
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Patients with a clinical diagnosis of retrograde cricopharyngeal dysfunction (RCPD). - Long-standing inability to belch. - Typical RCPD symptom constellation, including abdominal bloating, excessive gas, thoracic or cervical gurgling, and pressure symptoms. - Exclusion of structural pathology by clinical evaluation and esophagogastroduodenoscopy. - Treatment with transoral endoscopic botulinum toxin A injection into the cricopharyngeus muscle. - Written informed consent for the use of clinical data for research purposes.
Exclusion criteria
Exclusion criteria: - Clinically relevant dysphagia as the predominant symptom. - Structural disorders of the esophagus or upper gastrointestinal tract (e.g., strictures, diverticula, tumors, or eosinophilic esophagitis). - Neuromuscular or neurodegenerative disorders affecting swallowing or esophageal motility. - Previous surgical or endoscopic intervention involving the esophagus or upper esophageal sphincter. - Alternative diagnoses explaining the patient's symptom complex.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical response, defined as restoration of the ability to belch together with improvement of RCPD-associated symptoms, including abdominal bloating, gurgling, and thoracic pressure, assessed at 6 weeks and 3 months after botulinum toxin A injection. Outcome data are obtained from standardized clinical follow-up visits and patient-reported symptom assessment documented in the medical records. Data are retrospectively extracted from routine clinical documentation. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Treatment-related adverse events (particularly dysphagia, aspiration, and voice changes) - Findings of the pre-treatment diagnostic work-up (esophagogastroduodenoscopy and high-resolution esophageal manometry) - Persistence of symptom improvement at the 3-month follow-up. | — |
Countries
Germany
Contacts
Public ContactFriederike Weise
Uniklinik Düsseldorf, HNO Klinik
Outcome results
None listed